Ryufin

Ercros, S.A.

Spain · ES0125140A14 · reports in EUR · Europe

The answers

From the annual report for the year to Dec 31, 2024. Each line says what it is based on.

Is it growing?To watch
Revenue −7.6% in the year to Dec 31, 2024, on the year before.
Is it a good business?To watch
It earned −3.4% on its shareholders' equity in the year to Dec 31, 2024.
Is it safe?Fair
Equity is 49% of its assets, and operations brought in cash in the year.
Is the price fair?n/a
Not answered: no exchange publishes this company's price for free reuse, so there is no P/E here.

The year

Year to Dec 31, 2024, consolidated, in EUR.

€700M

revenue

-0.45%

operating margin

−€12M

net profit

Year by year

As filed; an earlier year can differ from its own report when the company restated it.

Dec 2021Dec 2022Dec 2023Dec 2024
Revenuen/an/a€758M€700M
Operating profit€62M€92M€13M−€3M
Earnings per share€0.43€0.64€0.29−€0.13
Dividend per sharen/an/an/a€0.10
Cash from operationsn/an/a€55M€10M
Capital spending€13M€27Mn/an/a
Cash€52M€58M€39M€37M
Total assets€710M€747M€683M€699M
Equity€332M€361M€363M€341M

What they do

In the company's own words, from the annual report.

la producción y comercialización de productos químicos y principios activos farmacéuticos genéricos La actividad del Grupo se desarrolla a través de tres segmentos de negocios [ver el capítulo C 1.3 d) del informe de gestión consolidado («IGC») y la nota 3 e) de las cuentas anuales consolidadas]: - La división de derivados del cloro (cloro, sosa cáustica, hipoclorito sódico, ácido clorhídrico, ATCC, PVC, oxidantes y otros productos). - La división de química intermedia (formaldehído y derivados). - La división de farmacia que produce principios activos farmacéuticos genéricos (eritromicinas, ácido fusídico y fosfomicinas, principalmente).

Source: the company’s annual financial report in ESEF, via filings.xbrl.org (XBRL International). Listed shares from ESMA’s FIRDS register; ESMA does not endorse this site. Ryufin computed the answers and ratios from the filed figures.